The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...
Carotuximab (ENV105) plus standard-of-care hormone therapy apalutamide (Erleada) demonstrated a progression-free survival ...
Following its Type A meeting with the FDA, Replimune reported that a forward pathway “has not been determined” to obtain ...
FDA fast track is intended to expedite the development of therapies that fill serious unmet medical needs. With this ...
ADG126 is a novel anti–CTLA-4 agent incorporating protease-cleavable masking technology that enables tumor-specific ...
Dr Kelly Paulson shares groundbreaking insights from the DeLLphi-303 study, highlighting new immunotherapy strategies for small cell lung cancer treatment.
During a live event, Taha Al-Juhaishi, MD, discussed long-term outcomes of treating blastic plasmacytoid dendritic cell neoplasm and how to navigate toxicities and transplant.
Through a search of electronic health records from the IKnowMed clinical oncology database (McKesson, Houston, TX, USA) the ...
The FDA has granted fast track designation to the antibody-drug conjugate (ADC) CRB-701 for the treatment of recurrent or ...
In recognition of September as Prostate Cancer Awareness Month, Daniel Petrylak, MD, professor of oncology and urology at ...
Sacituzumab govitecan is comprised of a humanized antitrophoblast cell-surface antigen 2 monoclonal antibody coupled to SN-38 ...
Results from the phase 2 study C-145-03 (NCT03083873) suggest the role of autologous tumor-infiltrating lymphocyte (TIL) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback